Compare SSRM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | BLTE |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.6B |
| IPO Year | N/A | 2021 |
| Metric | SSRM | BLTE |
|---|---|---|
| Price | $29.22 | $159.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $32.74 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 3.5M | 128.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.48 | N/A |
| Revenue Next Year | $4.31 | $492.11 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $56.68 |
| 52 Week High | $36.52 | $200.00 |
| Indicator | SSRM | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 43.71 |
| Support Level | $21.71 | $157.63 |
| Resistance Level | $33.49 | $161.28 |
| Average True Range (ATR) | 1.37 | 7.12 |
| MACD | -0.37 | -0.78 |
| Stochastic Oscillator | 5.38 | 19.71 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.